Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) – Investment analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Wednesday, January 4th. HC Wainwright analyst E. Arce forecasts that the company will post earnings per share of ($0.49) for the year. HC Wainwright has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($3.08) per share.
Get
Vera Therapeutics alerts:
Vera Therapeutics (NASDAQ:VERA – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.19).
Several other research firms have also recently commented on VERA. JPMorgan Chase & Co. raised their price target on Vera Therapeutics from $35.00 to $38.00 and gave the company an "overweight" rating in a report on Friday, November 18th. Wedbush cut Vera Therapeutics from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $33.00 to $8.00 in a report on Wednesday. Finally, Jefferies Financial Group cut Vera Therapeutics from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $32.00 to $6.00 in a report on Wednesday. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.75.
Vera Therapeutics Trading Down 2.1 %
Shares of VERA stock opened at $5.48 on Thursday. The business's 50 day moving average is $17.14 and its two-hundred day moving average is $17.93. Vera Therapeutics has a twelve month low of $5.20 and a twelve month high of $24.98. The company has a market capitalization of $151.57 million, a P/E ratio of -1.85 and a beta of -0.02. The company has a current ratio of 7.85, a quick ratio of 7.85 and a debt-to-equity ratio of 0.05.
Institutional Investors Weigh In On Vera Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank purchased a new stake in shares of Vera Therapeutics in the first quarter worth about $34,000. Swiss National Bank purchased a new stake in shares of Vera Therapeutics in the second quarter worth about $472,000. Bank of Montreal Can purchased a new stake in shares of Vera Therapeutics in the second quarter worth about $1,411,000. Alps Advisors Inc. purchased a new stake in shares of Vera Therapeutics in the second quarter worth about $219,000. Finally, Polar Asset Management Partners Inc. boosted its position in shares of Vera Therapeutics by 77.8% in the third quarter. Polar Asset Management Partners Inc. now owns 523,400 shares of the company's stock worth $11,154,000 after buying an additional 229,100 shares during the period. Hedge funds and other institutional investors own 88.64% of the company's stock.
Insider Activity
In other news, insider Joanne Curley sold 2,212 shares of Vera Therapeutics stock in a transaction on Friday, December 16th. The stock was sold at an average price of $19.49, for a total value of $43,111.88. Following the completion of the sale, the insider now owns 26,821 shares of the company's stock, valued at $522,741.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 14,091 shares of company stock valued at $261,974 over the last quarter. Company insiders own 43.10% of the company's stock.
About Vera Therapeutics
(Get Rating)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
Recommended Stories
- Get a free copy of the StockNews.com research report on Vera Therapeutics (VERA)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
